Kane Biotech Inc. (KNBIF)
USD 0.06
(0.0%)
USD 0.06
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -5.03 Million CAD | -29.41% |
| 2022 | -3.88 Million CAD | 15.52% |
| 2021 | -4.6 Million CAD | -23.89% |
| 2020 | -3.71 Million CAD | -287.08% |
| 2019 | -960.17 Thousand CAD | 70.56% |
| 2018 | -3.26 Million CAD | -17.04% |
| 2017 | -2.78 Million CAD | -9.32% |
| 2016 | -2.54 Million CAD | -49.05% |
| 2015 | -1.7 Million CAD | -5.89% |
| 2014 | -1.61 Million CAD | -11.58% |
| 2013 | -1.44 Million CAD | 0.83% |
| 2012 | -1.45 Million CAD | -19.52% |
| 2011 | -1.22 Million CAD | -25.47% |
| 2010 | -973.25 Thousand CAD | -10.94% |
| 2009 | -877.24 Thousand CAD | 18.54% |
| 2008 | -1.07 Million CAD | 1.2% |
| 2007 | -1.08 Million CAD | -14.04% |
| 2006 | -955.75 Thousand CAD | 5.34% |
| 2005 | -1 Million CAD | -67.56% |
| 2004 | -602.56 Thousand CAD | -48.58% |
| 2003 | -405.54 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.39 Million CAD | -16.57% |
| 2024 Q2 | 9.18 Million CAD | 757.86% |
| 2023 FY | -5.03 Million CAD | -29.41% |
| 2023 Q3 | -1.37 Million CAD | -42.41% |
| 2023 Q1 | -1.2 Million CAD | -38.08% |
| 2023 Q2 | -967.9 Thousand CAD | 19.42% |
| 2023 Q4 | -1.19 Million CAD | 13.13% |
| 2022 Q2 | -899.99 Thousand CAD | 18.82% |
| 2022 Q4 | -869.88 Thousand CAD | 13.99% |
| 2022 FY | -3.88 Million CAD | 15.52% |
| 2022 Q1 | -1.1 Million CAD | 12.63% |
| 2022 Q3 | -1.01 Million CAD | -12.38% |
| 2021 Q2 | -904.48 Thousand CAD | 0.44% |
| 2021 Q1 | -908.46 Thousand CAD | -11.26% |
| 2021 FY | -4.6 Million CAD | -23.89% |
| 2021 Q3 | -1.52 Million CAD | -68.36% |
| 2021 Q4 | -1.26 Million CAD | 16.68% |
| 2020 Q2 | -505.39 Thousand CAD | 62.94% |
| 2020 Q1 | -1.36 Million CAD | -17.91% |
| 2020 Q4 | -816.5 Thousand CAD | 20.8% |
| 2020 FY | -3.71 Million CAD | -287.08% |
| 2020 Q3 | -1.03 Million CAD | -103.99% |
| 2019 Q2 | 1.67 Million CAD | 354.86% |
| 2019 Q4 | -1.15 Million CAD | -40.79% |
| 2019 FY | -960.17 Thousand CAD | 70.56% |
| 2019 Q3 | -821.55 Thousand CAD | -149.03% |
| 2019 Q1 | -657.39 Thousand CAD | 2.29% |
| 2018 Q4 | -672.8 Thousand CAD | 32.5% |
| 2018 Q2 | -701.71 Thousand CAD | 21.14% |
| 2018 FY | -3.26 Million CAD | -17.04% |
| 2018 Q3 | -996.68 Thousand CAD | -42.04% |
| 2018 Q1 | -889.79 Thousand CAD | -0.13% |
| 2017 Q4 | -888.68 Thousand CAD | -2.24% |
| 2017 Q3 | -869.24 Thousand CAD | -9.95% |
| 2017 Q2 | -790.54 Thousand CAD | -232.59% |
| 2017 FY | -2.78 Million CAD | -9.32% |
| 2017 Q1 | -237.69 Thousand CAD | 52.47% |
| 2016 Q4 | -500.05 Thousand CAD | 18.83% |
| 2016 Q1 | -581.35 Thousand CAD | -21.59% |
| 2016 FY | -2.54 Million CAD | -49.05% |
| 2016 Q3 | -616.06 Thousand CAD | 27.63% |
| 2016 Q2 | -851.27 Thousand CAD | -46.43% |
| 2015 Q3 | -411.82 Thousand CAD | -23.71% |
| 2015 Q4 | -478.14 Thousand CAD | -16.1% |
| 2015 FY | -1.7 Million CAD | -5.89% |
| 2015 Q2 | -332.89 Thousand CAD | 31.66% |
| 2015 Q1 | -487.12 Thousand CAD | -6.99% |
| 2014 Q1 | -306.36 Thousand CAD | -142.88% |
| 2014 Q2 | -511.24 Thousand CAD | -66.88% |
| 2014 Q3 | -341.99 Thousand CAD | 33.11% |
| 2014 FY | -1.61 Million CAD | -11.58% |
| 2014 Q4 | -455.31 Thousand CAD | -33.13% |
| 2013 Q3 | -330.77 Thousand CAD | -1.47% |
| 2013 Q2 | -325.97 Thousand CAD | 50.94% |
| 2013 FY | -1.44 Million CAD | 0.83% |
| 2013 Q1 | -664.48 Thousand CAD | -59.57% |
| 2013 Q4 | -126.13 Thousand CAD | 61.87% |
| 2012 Q2 | -348.13 Thousand CAD | -14.44% |
| 2012 Q3 | -390.74 Thousand CAD | -12.24% |
| 2012 Q4 | -416.42 Thousand CAD | -6.57% |
| 2012 FY | -1.45 Million CAD | -19.52% |
| 2012 Q1 | -304.19 Thousand CAD | -1.76% |
| 2011 Q4 | -298.93 Thousand CAD | 12.44% |
| 2011 Q3 | -341.41 Thousand CAD | -52.2% |
| 2011 FY | -1.22 Million CAD | -25.47% |
| 2011 Q2 | -224.32 Thousand CAD | 37.07% |
| 2011 Q1 | -356.48 Thousand CAD | -81.02% |
| 2010 Q3 | -263.01 Thousand CAD | -11.32% |
| 2010 Q4 | -196.93 Thousand CAD | 25.12% |
| 2010 FY | -973.25 Thousand CAD | -10.94% |
| 2010 Q1 | -277.03 Thousand CAD | -161.98% |
| 2010 Q2 | -236.26 Thousand CAD | 14.72% |
| 2009 Q4 | -105.75 Thousand CAD | 65.62% |
| 2009 FY | -877.24 Thousand CAD | 18.54% |
| 2009 Q1 | -203.63 Thousand CAD | -51.34% |
| 2009 Q3 | -307.62 Thousand CAD | -18.21% |
| 2009 Q2 | -260.23 Thousand CAD | -27.79% |
| 2008 FY | -1.07 Million CAD | 1.2% |
| 2008 Q4 | -134.55 Thousand CAD | 63.93% |
| 2008 Q2 | -352.17 Thousand CAD | -62.2% |
| 2008 Q1 | -217.12 Thousand CAD | 25.56% |
| 2008 Q3 | -372.99 Thousand CAD | -5.91% |
| 2007 Q2 | -382.3 Thousand CAD | -96.61% |
| 2007 Q4 | -291.69 Thousand CAD | -32.26% |
| 2007 Q3 | -220.55 Thousand CAD | 42.31% |
| 2007 FY | -1.08 Million CAD | -14.04% |
| 2007 Q1 | -194.44 Thousand CAD | 45.05% |
| 2006 Q1 | -157.03 Thousand CAD | 43.92% |
| 2006 FY | -955.75 Thousand CAD | 5.34% |
| 2006 Q3 | -201.93 Thousand CAD | 16.87% |
| 2006 Q2 | -242.91 Thousand CAD | -54.69% |
| 2006 Q4 | -353.87 Thousand CAD | -75.25% |
| 2005 Q2 | -264.11 Thousand CAD | -25.8% |
| 2005 Q4 | -280.03 Thousand CAD | -9.58% |
| 2005 FY | -1 Million CAD | -67.56% |
| 2005 Q1 | -209.95 Thousand CAD | 15.31% |
| 2005 Q3 | -255.54 Thousand CAD | 3.24% |
| 2004 Q1 | -107.03 Thousand CAD | -111.74% |
| 2004 FY | -602.56 Thousand CAD | -48.58% |
| 2004 Q3 | -99.16 Thousand CAD | 33.2% |
| 2004 Q2 | -148.46 Thousand CAD | -38.7% |
| 2004 Q4 | -247.9 Thousand CAD | -149.99% |
| 2003 Q4 | -50.54 Thousand CAD | 71.09% |
| 2003 FY | -405.54 Thousand CAD | 0.0% |
| 2003 Q2 | -24.23 Thousand CAD | 0.0% |
| 2003 Q3 | -174.86 Thousand CAD | -621.41% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -191.417% |
| CSL Limited | 2.64 Billion USD | 100.191% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 93.285% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 23.449% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1741.282% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 109.502% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 107.729% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -176.519% |
| Mesoblast Limited | -87.95 Million USD | 94.277% |
| Marizyme, Inc. | -65.34 Million USD | 92.296% |
| Genus plc | 7.9 Million USD | 163.723% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 53.781% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -35.682% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 43.079% |
| ContraFect Corporation | -65.15 Million USD | 92.273% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -3.03% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -36.48 Million USD | 86.203% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 37.54% |
| MultiCell Technologies, Inc. | -380.07 USD | -1324419.957% |
| Accustem Sciences Inc. | -3.74 Million USD | -34.371% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 90.261% |
| EV Biologics, Inc. | -1.26 Million USD | -297.283% |
| Q BioMed Inc. | -2.05 Million USD | -145.316% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -34.854% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -111.44% |
| Biomind Labs Inc. | -1.21 Million USD | -314.562% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 36.302% |
| Skye Bioscience, Inc. | -37.64 Million USD | 86.627% |
| SQZ Biotechnologies Company | -79.46 Million USD | 93.665% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -33514.47% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 27.907% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -74.046% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 68.282% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -696.023% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 52.274% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -132.006% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 13.463% |
| GB Sciences, Inc. | -1.36 Million USD | -269.699% |
| Alpha Cognition Inc. | -13.77 Million USD | 63.448% |
| argenx SE | -295.05 Million USD | 98.294% |
| HST Global, Inc. | -146.21 Thousand USD | -3343.063% |
| Halberd Corporation | -79.67 Thousand USD | -6218.218% |
| Enzolytics Inc. | -2.17 Million USD | -131.258% |
| Resverlogix Corp. | -3.61 Million USD | -39.449% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -58.733% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 91.958% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 91.571% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 5236.84% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -62.298% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 172.699% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -158.259% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -26.708% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -66.354% |
| AVAX Technologies, Inc. | -6.41 Million USD | 21.51% |
| ONE Bio Corp. | 8.67 Million USD | 158.019% |
| Zenith Capital Corp. | -10.59 Million USD | 52.491% |
| Genscript Biotech Corporation | -95.47 Million USD | 94.727% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -21559.509% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -21.423% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -8229.008% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -151.063% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -186.881% |
| Agentix Corp. | -1.37 Million USD | -266.327% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -3.3 Million USD | -52.207% |
| Helix BioMedix, Inc. | -1.05 Million USD | -376.689% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -31.817% |
| BioStem Technologies, Inc. | -8.48 Million USD | 40.656% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1040.566% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -276.965% |
| LadRx Corporation | 400.44 Thousand USD | 1357.133% |
| Cell Source, Inc. | -5.32 Million USD | 5.396% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1111.638% |
| Regen BioPharma, Inc. | 1.02 Million USD | 591.848% |
| Regen BioPharma, Inc. | 1.02 Million USD | 591.848% |
| NovAccess Global Inc. | -4.76 Million USD | -5.555% |
| Affymax, Inc. | -14.42 Million USD | 65.099% |
| Itoco Inc. | -1.86 Million USD | -169.348% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -13.316% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -201.624% |
| CytoDyn Inc. | -49.84 Million USD | 89.9% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -6269.622% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -2106.711% |
| Qrons Inc. | -789.34 Thousand USD | -537.755% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -434.673% |
| SYBLEU INC | -180.3 Thousand USD | -2692.008% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -141.134% |
| Rebus Holdings, Inc. | -1.02 Million USD | -393.54% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -212.147% |
| Mobile Lads Corp. | -2.26 Million USD | -122.424% |
| International Stem Cell Corporation | -131 Thousand USD | -3742.827% |
| Bioxytran, Inc. | -4.28 Million USD | -17.619% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -9175.691% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -98.957% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 89.528% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -138.132% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -544.665% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -58.905% |
| Neutra Corp. | -233.46 Thousand USD | -2056.256% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 75.19% |
| PureTech Health plc | -65.69 Million USD | 92.337% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 76.329% |
| IXICO plc | -1.17 Million USD | -327.343% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 49.289% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 91.188% |
| CSL Limited | 2.64 Billion USD | 100.191% |
| Cellectis S.A. | -103.17 Million USD | 95.121% |